• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Polarity TE spins off IBEX Preclinical Research contract research organization

    5/26/22 11:15:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PTE alert in real time by email

    Dr. Josh Packer acquires IBEX and becomes CEO; maintains existing surgical research team

    LOGAN, Utah, May 26, 2022 /PRNewswire-PRWeb/ -- IBEX Preclinical Research, Inc., a trusted outsourcing partner and provider of preclinical surgical and toxicological studies in a variety of laboratory animal species, announced that it has been acquired by Josh Packer, DVM. IBEX provides in-vivo research services ranging from relatively simple single-dose pharmacokinetic studies to more complex projects requiring surgical instrumentation. Conducting both GLP and non-GLP non-clinical testing, IBEX supports life science, medical device companies and researchers that specialize in orthopedics, neurosurgical, soft tissue surgery, ophthalmology, and non-surgical processes assisting clients to successfully bring products to market.

    Founded in 2003 by Dr. Michael Larson, IBEX operated as part of the PolarityTE (NASDAQ:PTE) network since 2018 until the acquisition earlier this month. According to Packer, the acquisition allows leadership to play a more personal role in preclinical research and procedures, enabling even greater client care and support.

    "Since its inception, IBEX has built and maintained a team of highly skilled veterinary surgeons, clinical consultants, and pre-clinical scientists who excel in supporting the research needs of life science companies that aim to advance surgical and non-surgical care and outcomes across a variety of healthcare categories," said Dr. Packer. "I am thrilled to announce that we will be maintaining and building on the trusted surgical expertise and reputation that IBEX has earned as we advance the business and further expand the team."

    Dr. Packer and a group of minority investors purchased IBEX for $3.2 million in a deal that closed April 25. In order to serve the evolving needs of clients with even broader capabilities, IBEX recently completed a second expansion of its state-of-the-art facility in northern Utah. The latest construction brings the facility to over 12,000 square feet, including updates to an operating room, sterile preparation areas, expanded vivariums with additional housing for a range of small and large animals and enhanced 3-D imaging capabilities.

    Prior to acquiring IBEX, Dr. Packer was the lead preclinical surgeon for Medtronic PRL. Dr. Larson will remain with IBEX as lead consultant, while Harold Aberman, DVM, MSE will continue his role as a surgical and preclinical consultant.

    IBEX currently employs 14 clinical research professionals and will soon be hiring additional veterinarians, technicians, preclinical surgeons, and a preclinical scientist study director.

    Qualified candidates can learn more by emailing: [email protected]

    About Ibex Preclinical Research

    IBEX Preclinical Research, Inc., was founded in 2003 by Michael Larson, DVM, to provide preclinical testing services for pharmaceutical and medical device companies. IBEX is a proven partner and provider of preclinical surgical studies in a variety of laboratory animal species. By focusing on our core values of quality research and superior client service, IBEX has become a leading contract research organization serving life sciences companies in orthopedics, soft tissue, vascular surgery, and non-surgical studies such as nonsurgical drug toxicity and PK studies. To learn more, visit https://www.ibexresearch.com/.

    Media contact: Barbara Tabor, APR, [email protected]

    Media Contact

    Barbara Tabor, IBEX Preclinical Research, 651-230-9192, [email protected]

     

    SOURCE IBEX Preclinical Research

    Get the next $PTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company

      SALT LAKE CITY, Dec. 27, 2022 /PRNewswire/ --  PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a non-binding letter of intent (the "LOI") with Michael Brauser ("Brauser") for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash. As of December 23, 2022, there were 7,256,786 shares of the Company's common stock outstanding and unvested restricted stock units covering an additional 256,457 common shares. 

      12/27/22 8:30:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update

      SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022. Recent Business and Financial UpdatesAt the end of April 2022, PolarityTE began enrollment in its Phase III randomized controlled trial (RCT), which is a pivotal study under its open IND for SkinTE®. The Company estimates that it may be able to complete enrollment of 100 subjects sometime in the first six mon

      11/10/22 4:30:00 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company

      SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash. The offer is subject to various contingencies, including, among others, (1) settlement with warrant holders and satisfactory negotiations with insiders with change of control agreements, (2) minimum tender conditions, (3) a sixty-day due diligence period, and (4) satisfacti

      11/9/22 8:00:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Dyer Jeffrey Hansen was granted 42,986 shares, increasing direct ownership by 3,177% to 44,339 units

      4 - POLARITYTE, INC. (0001076682) (Issuer)

      1/30/23 4:30:42 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Dyer Jeffrey Hansen claimed ownership of 1,353 shares

      3 - POLARITYTE, INC. (0001076682) (Issuer)

      1/30/23 4:15:33 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Nolet Chris decreased direct ownership by 72% to 14,403 units

      4 - POLARITYTE, INC. (0001076682) (Issuer)

      1/17/23 4:30:29 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Financials

    Live finance-specific insights

    See more
    • PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update

      PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022. Recent Business and Financial UpdatesIn January 2022, PolarityTE was advised by the U.S. Food and Drug Administration (FDA) that it could conduct human clinical trials under PolarityTE's investigational new drug application (IND

      8/11/22 4:05:00 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

      SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accesse

      8/1/22 8:00:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Polarity TE spins off IBEX Preclinical Research contract research organization

      Dr. Josh Packer acquires IBEX and becomes CEO; maintains existing surgical research team LOGAN, Utah, May 26, 2022 /PRNewswire-PRWeb/ -- IBEX Preclinical Research, Inc., a trusted outsourcing partner and provider of preclinical surgical and toxicological studies in a variety of laboratory animal species, announced that it has been acquired by Josh Packer, DVM. IBEX provides in-vivo research services ranging from relatively simple single-dose pharmacokinetic studies to more complex projects requiring surgical instrumentation. Conducting both GLP and non-GLP non-clinical testing, IBEX supports life science, medical device companies and researchers that specialize in orthopedics, neurosurgical,

      5/26/22 11:15:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    SEC Filings

    See more
    • PolarityTE Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - POLARITYTE, INC. (0001076682) (Filer)

      8/18/23 4:54:40 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form NT 10-Q filed by PolarityTE Inc.

      NT 10-Q - POLARITYTE, INC. (0001076682) (Filer)

      8/15/23 4:40:32 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - POLARITYTE, INC. (0001076682) (Filer)

      8/15/23 4:30:36 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by PolarityTE Inc. (Amendment)

      SC 13G/A - POLARITYTE, INC. (0001076682) (Subject)

      2/14/23 11:11:43 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by PolarityTE Inc.

      SC 13G - POLARITYTE, INC. (0001076682) (Subject)

      8/23/22 11:30:24 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed

      SC 13G - POLARITYTE, INC. (0001076682) (Subject)

      2/16/21 5:19:31 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Leadership Updates

    Live Leadership Updates

    See more
    • PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

      SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately. "On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE.  "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we purs

      9/8/22 8:30:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations